{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T17:28:42Z","timestamp":1791739722117,"version":"4.3.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Chronic active Epstein-Barr virus infection (CAEBV) is a common infectious disease that often affects multiple organs or systems. However, it is liable to be neglected and misdiagnosed owing to its insidious onset, lack of specific findings in the early phase, and a general lack of awareness among clinicians.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>a 27-year-old woman case has been described who was initially misdiagnosed as drug-induced liver injury due to onset presentation of mild splenomegaly, recurrent liver dysfunction, and disputable pathological evidence of liver biopsy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>CAEBV complicated with natural killer (NK) cell lymphoma and hemophagocytic lymphohistiocytosis (HLH) was diagnosed by in situ hybridization of liver tissue section with EBV-encoded RNA -1 probe and flow cytometry of bone marrow.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>After admission, the patient received symptomatic treatment and antiviral therapy (combination of acyclovir and foscarnet sodium) as well as adjuvant treatment (thymosin alpha 1 and methylprednisolone); later, the patient received etoposide and dexamethasone for diagnosis of EBV associated HLH. Subsequently, the disease progressed to NK cell lymphoma and the patient received the revised EPOCH chemotherapy regimen [etoposide (100\u200amg\/d, d1\u20135), dexamethasone (7.5\u200amg\/d, d1\u20135; 5\u200amg\/d, d6\u201314), cyclophosphamide (0.8\u200ag\/d, d1\u20132), and pegaspargase (3750\u200au\/d, tid, d1\u20132)].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Although the patient received a series of therapies and other comprehensive measures, finally she died of gastrointestinal hemorrhage and multiple organ failure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Liver is one of the main target organs of EBV infection. In the clinical setting of unexplained fever and liver injury, it is necessary to be aware of CAEBV, as well as its fatal complication such as EBV associated NK cell lymphoma and HLH.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014032","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T13:07:26Z","timestamp":1548335246000},"page":"e14032","source":"Crossref","is-referenced-by-count":5,"title":["Chronic active EBV infection associated with NK cell lymphoma and hemophagocytic lymphohistiocytosis in a 27-year-old woman"],"prefix":"10.1097","volume":"98","author":[{"given":"Ya-Dong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ling","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Yuan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bo","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Yue","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanpi County Hospital, Cangzhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Xia","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Yan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev-virology-110615-042358","article-title":"Epstein-Barr virus: the path from latent to productive infection","volume":"3","author":"Chiu","year":"2016","journal-title":"Annu Rev Virol"},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.7150\/ijbs.16564","article-title":"Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis","volume":"12","author":"Li","year":"2016","journal-title":"Int J Biol Sci"},{"key":"R3-20230928","first-page":"817","article-title":"The understanding of Epstein-Barr virus associated lymphoproliferative disorder","volume":"45","author":"Zhou","year":"2016","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1346-8138.12322","article-title":"Epstein-Barr virus-associated T\/natural killer-cell lymphoproliferative disorders","volume":"41","author":"Park","year":"2014","journal-title":"J Dermatol"},{"key":"R5-20230928","first-page":"7110","article-title":"Systemic Epstein-Barr virus positive T-cell lymphoproliferative disease of childhood with hemophagocytic syndrome","volume":"7","author":"Chen","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.prp.2013.11.009","article-title":"EBV associated lymphomas in 2008 WHO classification","volume":"210","author":"Zhang","year":"2014","journal-title":"Pathol Res Pract"},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/ajh.20398","article-title":"Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection","volume":"80","author":"Okano","year":"2005","journal-title":"Am J Hematol"},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood.V98.2.280","article-title":"Clinical and virologic characteristics of chronic active Epstein-Barr virus infection","volume":"98","author":"Kimura","year":"2001","journal-title":"Blood"},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"74","DOI":"10.14740\/gr718e","article-title":"Epstein-Barr virus-associated acute liver failure present in a 67-year-old immunocompetent female","volume":"9","author":"Zhang","year":"2016","journal-title":"Gastroenterology Res"},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1586\/14737159.3.5.549","article-title":"Pathogenesis and diagnosis of X-linked lymphoproliferative disease","volume":"3","author":"Gilmour","year":"2003","journal-title":"Expert Rev Mol Diagn"},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3389\/fimmu.2017.01658","article-title":"Epstein-Barr virus-specific immune control by innate lymphocytes","volume":"8","author":"Munz","year":"2017","journal-title":"Front Immunol"},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3389\/fimmu.2016.00323","article-title":"NK cell influence on the outcome of primary Epstein-Barr virus infection","volume":"7","author":"Chijioke","year":"2016","journal-title":"Front Immunol"},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20230928","first-page":"241","article-title":"Primary immunodeficiencies associated with EBV disease","volume":"390","author":"Cohen","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00431-006-0258-1","article-title":"Familial and acquired hemophagocytic lymphohistiocytosis","volume":"166","author":"Janka","year":"2007","journal-title":"Eur J Pediatr"},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/v9110352","article-title":"Therapeutic strategies against Epstein-Barr virus-associated cancers using proteasome inhibitors","volume":"9","author":"Hui","year":"2017","journal-title":"Viruses"},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00277-013-1925-8","article-title":"A high sIL-2R\/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome","volume":"93","author":"Tsuji","year":"2014","journal-title":"Ann Hematol"},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1080\/10428194.2017.1387902","article-title":"FDG-PET\/CT findings of chronic active Epstein-Barr virus infection","volume":"93","author":"Toriihara","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"R19-20230928","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/blood-2010-11-316745","article-title":"Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States","volume":"117","author":"Cohen","year":"2011","journal-title":"Blood"},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"R21-20230928","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1086\/367988","article-title":"Prognostic factors for chronic active Epstein-Barr virus infection","volume":"187","author":"Kimura","year":"2003","journal-title":"J Infect Dis"},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood-2002-01-0039","article-title":"Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection","volume":"100","author":"Savoldo","year":"2002","journal-title":"Blood"},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/ajh.20430","article-title":"Successful umbilical cord blood transplantation for severe chronic active Epstein-Barr virus infection after the double failure of hematopoietic stem cell transplantation","volume":"80","author":"Ishimura","year":"2005","journal-title":"Am J Hematol"},{"key":"R24-20230928","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/10245332.2017.1385191","article-title":"Multivariate analysis of prognosis for patients with natural killer\/T cell lymphoma-associated hemophagocytic lymphohistiocytosis","volume":"23","author":"Jin","year":"2018","journal-title":"Hematology"},{"key":"R25-20230928","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/bmt.2010.122","article-title":"Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection","volume":"46","author":"Kawa","year":"2011","journal-title":"Bone Marrow Transplant"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201901110-00047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T03:18:51Z","timestamp":1695871131000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201901110-00047"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014032","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}